Single-Inhaler Triple Therapy Reduces Composite AE Risk vs Dual Therapy in COPD
Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations.
